Apr 30, 2025 10:00
PBYI - PUMA BIOTECHNOLOGY INC
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 4.85 0.12 (2.37%) | --- | 0.0 (0.0%) | -0.02 (-0.3%) | --- | 0.12 (2.37%) | --- | --- |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Market
Earnings & Ratios
- Basic EPS:
- 0.12
- Diluted EPS:
- 0.12
- Basic P/E:
- 41.375
- Diluted P/E:
- 41.375
- RSI(14) 1m:
- 100.0
- VWAP:
- 4.97
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|
Related News
Jul 18, 2024 23:58
Jul 03, 2024 01:45
Jul 03, 2024 01:45
Jul 03, 2024 01:45
Jun 04, 2024 15:01
May 24, 2024 15:57
May 20, 2024 13:59
May 03, 2024 15:31
May 02, 2024 22:05